home / stock / tgna / tgna quote
Last: | $13.54 |
---|---|
Change Percent: | -0.3% |
Open: | $13.31 |
Close: | $13.54 |
High: | $13.555 |
Low: | $13.28 |
Volume: | 1,317,789 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$13.54 | $13.31 | $13.54 | $13.555 | $13.28 | 1,317,789 | 04-18-2024 |
$13.27 | $13.6 | $13.27 | $13.63 | $13.25 | 1,313,191 | 04-17-2024 |
$13.47 | $13.33 | $13.47 | $13.57 | $13.18 | 1,857,421 | 04-16-2024 |
$13.39 | $13.65 | $13.39 | $13.77 | $13.355 | 1,376,952 | 04-15-2024 |
$13.6 | $13.75 | $13.6 | $13.8 | $13.55 | 1,524,323 | 04-12-2024 |
$13.84 | $13.81 | $13.84 | $13.96 | $13.695 | 1,522,987 | 04-11-2024 |
$13.79 | $14.13 | $13.79 | $14.15 | $13.74 | 1,706,084 | 04-10-2024 |
$14.3 | $14.11 | $14.3 | $14.305 | $14.1 | 1,196,992 | 04-09-2024 |
$14.14 | $14.23 | $14.14 | $14.3375 | $14.12 | 1,401,595 | 04-08-2024 |
$14.21 | $14.17 | $14.21 | $14.25 | $14.0806 | 1,796,504 | 04-05-2024 |
$14.24 | $14.54 | $14.24 | $14.625 | $14.22 | 2,163,018 | 04-04-2024 |
$14.41 | $14.37 | $14.41 | $14.428 | $14.26 | 1,216,098 | 04-03-2024 |
$14.39 | $14.63 | $14.39 | $14.76 | $14.325 | 1,538,251 | 04-02-2024 |
$14.68 | $14.92 | $14.68 | $14.99 | $14.625 | 1,403,704 | 04-01-2024 |
$14.94 | $14.83 | $14.94 | $14.98 | $14.83 | 2,011,412 | 03-29-2024 |
$14.94 | $14.83 | $14.94 | $14.98 | $14.83 | 2,011,412 | 03-28-2024 |
$14.85 | $14.52 | $14.85 | $14.85 | $14.52 | 2,053,824 | 03-27-2024 |
$14.46 | $14.39 | $14.46 | $14.49 | $14.27 | 1,627,933 | 03-26-2024 |
$14.29 | $14.1 | $14.29 | $14.3 | $14.05 | 1,445,513 | 03-25-2024 |
$14.05 | $14.39 | $14.05 | $14.45 | $13.97 | 1,677,581 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-04-15 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...